Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
- Shiffman M.L.
- Suter F.
- Bacon B.R.
- Nelson D.
- Harley H.
- Sola R.
- Shafran S.D.
- Barange K.
- Lin A.
- Soman A.
- Zeuzem S.
- Crawford D.
- Leggett L.
- Roberts S.
- Weltman M.
- Greenbloom S.
- Menon K.
- Bourliere M.
- Brissot P.
- Bronowicki J.P.
- Doffoel M.
- Hezode C.
- Marcellin P.
- Tran A.
- Zarski J.P.
- Avci O.
- Berg T.
- Potthoff O.
- Rasenack J.
- Ross O.
- von Wagner M.
- Ascione A.
- Brillanti S.
- Brunetto M.
- Bruno R.
- Bruno S.
- Cane E.
- Aguilar J.
- Barcena R.
- Diago M.
- Enriquez J.
- Garcia-Samaniego J.
- Moreno R.
- Planas R.
- Rincon D.
- Sola R.
- Testillano M.
- Anand B.
- Bilir B. Bahri
- Balan V.
- Bank L.
- Barranco E.
- Berg C.
- Bernstein D.
- Bloom J.
- Bonkovsky H.
- Box T.
- Brau N.
- Bzowej N.
- Cassidy W.
- Clain D.
- Corasanti J.
- Davis M.
- DeJesus E.
- Delich P.
- Esposito S.
- Etzkorn K.
- Flora K.
- Fried M.
- Fromm H.
- Ghalib R.
- Gibas A.
- Godofsky E.
- Gompf S.
- Gordon S.
- Gordon F.
- Hammond G.
- Harrison S.
- Herrera J.
- Ho S.
- Howell C.
- Joshi S.
- Keeffe E.
- Kranz K.
- Kwo P.
- Lake-Bakaar G.
- Larson A.
- Levin A.
- Lok A.
- Lucey M.
- Lyons M.
- Malet P.
- Malik P.
- Manch R.
- Mehra S.
- Mihas A.
- Mikolich D.
- Morgan T.
- Muir A.
- Nguyen R.
- Nunes D.
- Nyberg L.
- O'Brien C.
- Pappas S.
- Pauly M.
- Pedrosa M.
- Perkel M.
- Person J.
- Pockros P.
- Post A.
- Poulos J.
- Powell R.
- Raj V.
- Reed A.
- Reindollar R.
- Riley T.
- Rodriguez-Torres M.
- Rubin R.
- Sahagun G.
- Schmidt W.
- Sepe T.
- Shaw-Stiffel T.
- Sheikh A.
- Sherman K.
- Smith C.
- Stevens D.
- Sulkowski M.
- Toro D.
- Torres E.
- Tran T.
- Tsai N.
- Wohlman R.
- Wright W.
- Wruble L.
- Younossi Z.
DOIAbstract
BACKGROUND: Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for 24 weeks. We conducted a large, randomized, multinational, noninferiority trial to determine whether similar efficacy could be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin. METHODS: We randomly assigned 1469 patients with HCV genotype 2 or 3 to receive 180 mug of peginterferon alfa-2a weekly, plus 800 mg of ribavirin daily, for either 16 or 24 weeks. A sustained virologic response was defined as an undetectable serum HCV RNA level (<50 IU per milliliter) 24 weeks after the end of treatment. RESULTS: T...
Add to ORKG